Detalhe da pesquisa
1.
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
N Engl J Med
; 386(19): 1793-1803, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35544387
2.
Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
J Infect Dis
; 226(11): 1985-1991, 2022 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36082606
3.
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
Am J Gastroenterol
; 116(9): 1924-1928, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465694
4.
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med
; 376(22): 2134-2146, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28564569
5.
Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials.
Hepatol Res
; 50(10): 1109-1117, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32614468
6.
Sofosbuvir/velpatasvir for 12â¯weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
J Hepatol
; 71(4): 660-665, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31195062
7.
In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir.
J Clin Microbiol
; 57(4)2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30728196
8.
In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
J Viral Hepat
; 26(8): 991-1001, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31009123
9.
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
J Viral Hepat
; 26(6): 770-773, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30663168
10.
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
J Hepatol
; 68(5): 895-903, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29221887
11.
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12â¯weeks in HCV DAA-experienced patients.
J Hepatol
; 69(6): 1221-1230, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30098373
12.
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
N Engl J Med
; 373(8): 705-13, 2015 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26196665
13.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
N Engl J Med
; 373(27): 2608-17, 2015 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-26575258
14.
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Gastroenterology
; 153(1): 113-122, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28390869
15.
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Hepatology
; 65(6): 1803-1809, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28220512
16.
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Hepatology
; 66(4): 1083-1089, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28498551
17.
Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
Liver Int
; 38(9): 1552-1561, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29297980
18.
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
Ann Intern Med
; 166(2): 109-117, 2017 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27842383
19.
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
J Hepatol
; 66(4): 703-710, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27923693
20.
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
J Hepatol
; 66(5): 910-918, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28108232